The median LOS was 9 days (range 5 – 67 days). In our study cohort, 61% had at least one comorbid condition. Among recipients > 60 years the presence of > 1 comorbidity

was associated with a higher likelihood of PLOS (p=0.025) and increasing CCI correlates with PLOS. In contrast in those < 60 years, comorbidity was not associated with PLOS (p=0.248). Furthermore, there was no difference in PLOS when recipients > 60 years without comorbidity was compared to < 60 years with comorbidity (p=0.66). The median LOS for older recipients without comorbidity was 11 days compared to 14.3 days for those with > 1 comorbidity. Conclusion: Pre-transplant comorbidity in older candidates with ESLD is an independent predictor of LOS post LT. Thus comorbid burden in older candidates significantly impacts resource utilization. check details Small molecule library datasheet The CCI is a simple, reproducible and readily available tool that can be incorporated in the pre-operative risk assessment

of older LT candidates and it can be utilized as a health service metric by public health policy makers and transplant programs in evaluating and assessing current healthcare reimbursement schemes. Disclosures: Edson S. Franco – Grant/Research Support: bayers, gilead, eisai Elizabeth Cece Fallon – Speaking and Teaching: Janssen Pharmaceuticals, AbbVie Pharmaceuticals Erin Parkinson – Speaking and Teaching: Gilead, BMS Angel Alsina – Advisory Committees or Review Panels: Bayer; Speaking and Teaching: Bayer, Novartis The following people have nothing to disclose: Nyingi M. Kemmer, Chris Albers, Husssein Osman-Mohamed, Jennifer Horkan

The AASLD/IDSA has published recommendations for the use of the 2nd generation direct acting antivirals (DAA). The cost of these drugs has put pressure on insurance companies (IC) Alanine-glyoxylate transaminase to fulfill the patient and physician demand for HCV treatment. In this study we sought to determine the approval rates for various combinations of peginterferon (Peg), ribavirin (R), sofosbuvir (Sof), and simeprevir (Sim) in a single US center. METHODS: Consecutive prescriptions for HCV treatment from 12/9/13 – 5/9/14 with a final decision rendered by the patient’s IC were included. Rates and time to approval, prior therapy response, insurance type, cirrhosis, and liver transplant (LT) status were analyzed. Chi-square and t-test were applied. 172 patients were prescribed treatment: Peg/R/Sof: 28 (16%), R/Sof: 45 (26%), and Sof/Sim: 99 (58%). 88 (51%) had government and 84 (49%) had private insurance. There were 85 (49%) cirrhotics. 29 (17%) had undergone LT prior to treatment request. 54 (31%) were prior treatment naïve, 15 (9%) relapsed, and 103 (60%) partial or non-response (P/NR). RESULTS: 153 (89%) patients were approved for treatment (Peg/R/Sof: 28 (100%), R/Sof: 42 (93%), and Sof/Sim: 83 (84%). The interval for receiving approval was similar in all groups (Peg/R/Sof: 22 days, R/Sof: 20 days, and Sof/ Sim: 21 days, p=0.78).